New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
07:49 EDTPRGO, GSKPerrigo commences launch of clobetasol emulsion propionate foam, 0.05%
Perrigo (PRGO) announced that it has launched clobetasol emulsion propionate foam, 0.05%, the generic equivalent of Olux -E Foam, 0.05%. Perrigo will commence shipment of the product immediately. As Perrigo was the first generic filer against this product, it has 180 days of generic exclusivity. The launch date was agreed upon in a 2012 litigation settlement between Perrigo and GlaxoSmithKline (GSK).
News For PRGO;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:21 EDTGSKLigand partner Glaxo files sNDA seeking additional indication for Promacta
Subscribe for More Information
December 19, 2014
10:12 EDTPRGOHigh option volume stocks
Subscribe for More Information
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 17, 2014
13:32 EDTPRGOPerrigo jumps after analyst discusses potential takeover by Teva
Subscribe for More Information
09:26 EDTPRGOPerrigo would be good acquisition for Teva, says RBC Capital
RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use